ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Gynecologic Cancers

Targeted Therapy Combo Shows Benefit in Breast and Ovarian Cancer

Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients. Image © iQoncept / Shutterstock.com.

Gynecologic Cancers

Beta-blockers were associated with increased overall survival in women with epithelial ovarian cancer, according to a retrospective study.

Testing women for non-BRCA gene mutations that can confer breast or ovarian cancer risk has clinical management consequences for both the women and their family members.

Women younger than 35 with low-grade serous carcinoma of the ovary or peritoneum or those who still had persistent disease at the completion of primary therapy were found to have worse disease outcomes.

A study has found that mutations in the genes RAD51C and RAD51D confer risk for epithelial ovarian cancer, causing approximately one in every 90 high-grade and one in every 120 epithelial ovarian cancer occurrences.

According to a recent study, the use of oral birth control pills has prevented 200,000 cases of endometrial cancer over the last 10 years.

Despite trials showing a benefit when combining IP and IV chemo for ovarian cancer, fewer than 50% of eligible patients are currently receiving this treatment.

The FDA has granted Orphan Drug Designation to the immunotherapy DPX-Survivac, which is in development for the treatment of ovarian cancer.

Pages

Subscribe to Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.